secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001770787-24-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics reports preliminary Q4 revenue of $184M, up 18% YoY; instruments up 72%
--------------------------------------------------------------------------------

- Preliminary Q4 2023 revenue ~$184.0M, 18% growth over prior year; full-year revenue ~$618.7M, up 20%.
- Q4 instruments revenue ~$38.4M (+72% YoY), driven by Spatial ($27.2M) and Chromium ($11.1M).
- Q4 consumables revenue ~$140.3M (+7% YoY); services revenue ~$5.3M (+129% YoY).
- Cumulative instruments sold exceeded 5,900 as of year-end 2023, including over 5,150 Chromium, 500 Visium, 250 Xenium.
- Final audited results expected in February 2024 earnings call; preliminary figures subject to adjustment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078724000004/0001770787-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078724000004/txg-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001770787-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer